Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma
暂无分享,去创建一个
Lin Qi | Wenchao Zhang | Fangyue Chen | Zhihang Li | Zhimin Yang | Lu Wang
[1] Huiren Tao,et al. Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma. , 2023, International immunopharmacology.
[2] Zhu Weiwei,et al. An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning , 2023, Frontiers in Pharmacology.
[3] Haowen Chen,et al. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR , 2022, International journal of biological sciences.
[4] A. Alimonti,et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer , 2022, Nature Communications.
[5] M. Benelli,et al. PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer , 2022, NPJ breast cancer.
[6] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[7] Robert F. Gruener,et al. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..
[8] Q. Zou,et al. Correction: IQGAP1 promotes anoikis resistance and metastasis through Rac1-dependent ROS accumulation and activation of Src/FAK signalling in hepatocellular carcinoma , 2021, British Journal of Cancer.
[9] Christopher S. Hughes,et al. Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma , 2021, Cancer discovery.
[10] D. Nitti,et al. E2F1 copy number variations in germline and breast cancer: a retrospective study of 222 Italian women , 2021, Molecular medicine.
[11] Hannah R. Weisman,et al. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma , 2021, Nature Medicine.
[12] M. Delorenzi,et al. Tailoring the resolution of single-cell RNA sequencing for primary cytotoxic T cells , 2021, Nature Communications.
[13] X. Zu,et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer , 2021, Theranostics.
[14] V. Seshan,et al. The association between tumor mutational burden and prognosis is dependent on treatment context , 2020, Nature genetics.
[15] Wei-Chun Chang,et al. Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy , 2020, International journal of molecular sciences.
[16] A. Gronchi,et al. Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.
[17] F. Bertucci,et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Matthew D. Smith,et al. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. , 2019, The Journal of clinical investigation.
[19] D. Jackson,et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.
[20] S. Mocellin,et al. E2F1 germline copy number variations and melanoma susceptibility , 2019, Journal of translational medicine.
[21] U. Röhrig,et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond , 2019, Nature Reviews Drug Discovery.
[22] J. Madore,et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.
[23] C. Frezza. Histidine metabolism boosts cancer therapy , 2018, Nature.
[24] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[25] Christian M. Metallo,et al. The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. , 2018, Molecular cell.
[26] Steven J. M. Jones,et al. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.
[27] Giuseppe Opocher,et al. Copy number variations of E2F1: a new genetic risk factor for testicular cancer. , 2017, Endocrine-related cancer.
[28] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[29] S. Ogino,et al. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] S. Nie,et al. Copy‐number variation of MCL1 predicts overall survival of non‐small‐cell lung cancer in a Southern Chinese population , 2016, Cancer medicine.
[31] I. Peták,et al. Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma , 2016, Virchows Archiv.
[32] Yan Xu,et al. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells , 2014, Oncogene.
[33] Khin Thway,et al. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies , 2014, Nature Reviews Clinical Oncology.
[34] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[35] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[36] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[37] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[38] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[39] E. Giannoni,et al. Anoikis: an emerging hallmark in health and diseases , 2012, The Journal of pathology.
[40] Matthew D. Wilkerson,et al. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..
[41] N. Kyprianou,et al. Targeting anoikis resistance in prostate cancer metastasis. , 2010, Molecular aspects of medicine.
[42] W. Lam,et al. PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.
[43] P. Sorensen,et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. , 2007, Cancer research.
[44] O. Myklebost,et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential , 2007, BMC Genomics.
[45] J. Averill,et al. Increased gene copy number of The transcription factor E2F1 In malignant melanoma , 2006, Cancer biology & therapy.
[46] D. Rose,et al. Obesity, adipocytokines, and insulin resistance in breast cancer , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[47] David Botstein,et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. , 2003, The American journal of pathology.
[48] D. Botstein,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[49] T. Eckes,et al. A Graph Theoretic Criterion for Determining the Number of Clusters in a Data Set. , 1992, Multivariate behavioral research.